Research programme: antifungals - Eli Lilly/Phytera
Latest Information Update: 23 Jan 2007
At a glance
- Originator Eli Lilly; Phytera
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 22 Jan 2007 Discontinued - Preclinical for Mycoses in USA (unspecified route)
- 30 Jan 2001 Preclinical development for Mycoses in USA (Unknown route)